Showing results (61-70 of 85) with videos related to
Sort By:
Pageof 9
Cancer Immunology, Immunotherapy : CII|October 30, 2020
Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicitySimone Punt, Shruti Malu, Jodi A McKenzie, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable MelanomaElizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.NPJ Genomic Medicine|May 23, 2026
Germline variants in cancer susceptibility genes among patients with mucosal melanomaAfsaneh Amouzegar, Xiaogang Wu, James P Long, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.Journal for Immunotherapy of Cancer|March 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanomaLi Zhou, Milton Jose Barros E Silva, Edward Hsiao, et al.Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.Cell Metabolism|April 10, 2018
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyTina Cascone, Jodi A McKenzie, Rina M Mbofung, et al.Cancer Discovery|April 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II studySalah-Eddine Bentebibel, Daniel J McGrail, Veena Kochat, et al.Nature Medicine|March 30, 2023
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim resultsIsabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.Pageof 9